I would add to the above that it's possibly the 'pharmacokinetics' of NNZ-2591 (bioavailability, stability, half-life), rather than it's mechanism of action, that has caused Jon to call it the "jewel in the crown" for Neuren.
It looks to me Neuren may have made some compromises to get Trofinitide to work. NNZ-2591 appears closer to the 'ideal' pharmacokinetics you'd want in an effective drug. If its half-life is longer than Trofinitide too then doubly so.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.28 |
Change
0.080(0.56%) |
Mkt cap ! $1.772B | |||
| Open | High | Low | Value | Volume |
| $14.23 | $14.71 | $14.03 | $2.961M | 207.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 446 | $14.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.28 | 313 | 8 |
View Market Depth
| Last trade - 13.02pm 30/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |